A phase I trial, which enrolled 26 patients with anti-PD-1/PD-L1-resistant melanoma (n = 12), non-small cell lung cancer (n = 1) and renal cell carcinoma (n = 13), evaluated the safety of the CD40 agonist APX005M (sotigalimab) and CSF1R inhibitor (cabiralizumab) with or without nivolumab. The gene discussed is CD40; the disease is hereditary clear cell renal cell carcinoma.